IL31 Canine
Sf9, Baculovirus cells.
IL-31, Interleukin 31, IL31.
Greater than 95.0% as determined by SDS-PAGE.
Description
IL31 Canine produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 136 amino acids (24-159 aa) and having a molecular mass of 15.3kDa.
IL31 is purified by proprietary chromatographic techniques.
Product Specs
IL-31, a cytokine primarily produced by activated Th2 cells, interacts with a heterodimeric receptor complex comprising IL-31 Receptor Anatagonist and Onconstatin-M Receptor. This receptor complex is constitutively expressed on epithelial cells and keratinocytes. IL-31 plays a crucial role in the pathogenesis of allergic skin disorders and the regulation of other allergic diseases like asthma. In atopic dermatitis, IL-31 contributes to itching and promotes scratching behavior in NC/Nga mice. Its expression is linked to CLA(+) T cells and is implicated in the development of skin inflammation and pruritus associated with atopic dermatitis. Furthermore, IL-31 acts as a potent inducer of proinflammatory mediators in human colonic SEMFs. Being a proinflammatory cytokine secreted by Th2 cells, elevated serum IL-31 levels are observed in individuals with atopic dermatitis. IL-31 exhibits pleiotropic physiological functions, influencing a wide array of immune and non-immune cells. Its diverse roles encompass the regulation of hematopoiesis and immune responses, involvement in inflammatory bowel disease, contribution to airway hypersensitivity, and participation in dermatitis.
Canine IL31, expressed in Sf9 Baculovirus cells, is a single, glycosylated polypeptide chain. It comprises 136 amino acids (specifically, amino acids 24-159) and exhibits a molecular weight of 15.3kDa. The purification of IL31 is achieved through proprietary chromatographic methods.
The IL31 solution is provided at a concentration of 0.25mg/ml. It is formulated in a buffer consisting of 20% Glycerol and Phosphate Buffered Saline, maintaining a pH of 7.4.
The purity of IL31 is determined by SDS-PAGE analysis and is consistently greater than 95.0%.
IL-31, Interleukin 31, IL31.
Sf9, Baculovirus cells.
SHMAPTHQLP PSDVRKIILE LQPLSRGLLE DYQKKETGVP ESNRTLLLCL TSDSQPPRLN
SSAILPYFRA IRPLSDKNII DKIIEQLDKL KFQHEPETEI SVPADTFECK SFILTILQQF SACLESVFKS
LNSGPQ
Product Science Overview
Interleukin-31 (IL-31) is a cytokine that plays a significant role in the immune system, particularly in the context of allergic reactions and inflammatory responses. It is part of the gp130/interleukin-6 cytokine family and is primarily produced by activated T helper 2 (Th2) cells . In dogs, IL-31 is known to induce pruritus (itchiness), which is a common symptom in various allergic skin conditions such as canine atopic dermatitis (CAD) .
Recombinant canine IL-31 is produced using recombinant DNA technology, which involves inserting the gene encoding IL-31 into a suitable expression system, such as bacteria or mammalian cells, to produce the protein in large quantities. This recombinant protein can then be purified and used for various research and therapeutic purposes .
IL-31 interacts with a heterodimeric receptor composed of IL-31 receptor alpha (IL-31RA) and oncostatin M receptor beta (OSMR). These receptors are constitutively expressed on epithelial cells and keratinocytes, which are key cell types involved in the skin’s response to allergens .
Canine atopic dermatitis is a chronic inflammatory skin disease characterized by itching, redness, and skin lesions. IL-31 is a critical mediator of pruritus in this condition. When IL-31 binds to its receptors on keratinocytes and other skin cells, it triggers a cascade of signaling events that lead to the release of pro-inflammatory cytokines and chemokines, exacerbating the inflammatory response and itchiness .
The recombinant form of canine IL-31 has been instrumental in developing therapeutic strategies to manage pruritus in dogs. One such therapeutic is lokivetmab (Cytopoint), a monoclonal antibody that specifically targets IL-31. Lokivetmab binds to IL-31, preventing it from interacting with its receptors and thereby reducing the itchiness and inflammation associated with CAD .
Studies have shown that a single subcutaneous injection of lokivetmab can significantly reduce pruritus in dogs for up to 42 days, providing a long-lasting and effective treatment option for managing CAD .
